English
Arabic
Chinese (Simplified)
Dutch
Esperanto
French
German
Greek
Italian
Japanese
Korean
Portuguese
Russian
Spanish
UrduAn international team of neuro-oncology researchers and clinicians has released new recommendations for good clinical practice regarding the use of artificial intelligence methods to more accurately diagnose, monitor and treat brain cancer.
Tag: Neuro-oncology
Four MD Anderson researchers elected AAAS Fellows
In recognition of their significant achievements in the realm of cancer care and research, four researchers at The University of Texas MD Anderson Cancer Center have been elected fellows of the American Association for the Advancement of Science (AAAS). This prestigious distinction stands as one of the highest accolades within the scientific research community.
Pioneering Sylvester Physician Elected to Society of Neuro-Oncology Board
Macarena de la Fuente, MD, chief of neuro-oncology at Sylvester Comprehensive Cancer Center, has been elected to the Society of Neuro-Oncology (SNO)’s board of directors. She becomes the first Hispanic elected to the multidisciplinary board.
Using neuropsychology to heal from cancer treatment
Ken Kessler had been diagnosed with glioblastoma, a rare and aggressive brain tumor. In April 2022, he had his first procedure at the University of Michigan Rogel Cancer Center to remove as much of the tumor as possible.
Advancing Care and Innovation for Pediatric Brain Tumors
The Brain Tumor Center at Children’s Hospital Los Angeles takes a team approach—and offers one of the largest clinical trial programs of its kind. The Brain Tumor Center at Children’s Hospital Los Angeles is one of the largest and most comprehensive pediatric brain tumor programs in the country, integrating experts from multiple specialty areas into a coordinated treatment team.
December 2022 Issue of Neurosurgical Focus: “Personalized Medicine in the Treatment of Neuro-Oncology and Neurosurgical Disease”
Announcement of contents of the December 2022 issue of Neurosurgical Focus
Sylvester Leads Study on New Treatment Option for Brain Tumor that Relapses or Fails to Respond to Standard of Care
Taken twice daily, oral olutasidenib helped to stabilize relapsed or refractory gliomas in heavily pretreated patients with less toxicity than standard of care treatment, according to a study led by Sylvester Comprehensive Cancer Center at the University of Miami School…